nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.12.2015 | Neuro-Ophthalmology (A Kawasaki, Section Editor)

Atypical Optic Neuritis

verfasst von: Eric D. Gaier, Katherine Boudreault, Joseph F. Rizzo III, Julie Falardeau, Dean M. Cestari

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Classic demyelinative optic neuritis is associated with multiple sclerosis and typically carries a good prognosis for visual recovery. This disorder is well characterized with respect to its presentation and clinical features by baseline data obtained through the optic neuritis treatment trial and numerous other studies. Atypical optic neuritis entails clinical manifestations that deviate from this classic pattern of features. Clinical signs and symptoms that deviate from the typical presentation should prompt consideration of less common etiologies. Atypical features to consider include lack of pain, simultaneous or near-simultaneous onset, lack of response to or relapse upon tapering from corticosteroids, or optic nerve head or peripapillary hemorrhages. The most important alternative etiologies to consider and the steps towards their respective diagnostic evaluations are suggested for these atypical features.

Perkin GD, Rose CF. Optic neuritis and its differential diagnosis. Oxford: Oxford University Press; 1979.

Group Ons. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991;109(12):1673–8.CrossRef

Mcdonald WI. Doyne Lecture. The significance of optic neuritis. Trans Ophthalmol Soc U K. 1983;103(Pt 3):230–46.PubMed

Rizzo III JF, Lessell S. Optic neuritis and ischemic optic neuropathy. Overlapping clinical profiles. Arch Ophthalmol. 1991;109(12):1668–72.CrossRefPubMed

Rizzo III JF, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109(9):1679–84.CrossRefPubMed

Beck RW, Cleary PA, Anderson Jr MM, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581–8.CrossRefPubMed

Group Ons. Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology. 2008;115(6):1079–82.CrossRef

Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the optic neuritis treatment trial. Ophthalmology. 1994;101(11):1771–8.CrossRefPubMed

Liu GT, Volpe NJ, Galetta SL. Neuro-ophthalmology: diagnosis and management. 2nd ed. Philadelphia: W.B. Saunders; 2001.

10.

Gartner S. Optic neuropathy in multiple sclerosis. Optic Neuritis Ama Arch Ophthalmol. 1953;50(6):718–26.CrossRefPubMed

11.

Schlossman A, Phillips CC. Optic neuritis in relation to demyelinating diseases; a clinical study. Am J Ophthalmol. 1954;37(4):487–94.CrossRefPubMed

12.

Cohen MM, Lessell S, Wolf PA. A prospective study of the risk of developing multiple sclerosis in uncomplicated optic neuritis. Neurology. 1979;29(2):208–13.CrossRefPubMed

13.

Rizzo III JF, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology. 1988;38(2):185–90.CrossRefPubMed

14.

Ons G. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology. 1997;49(5):1404–13.CrossRef

15.

Group Ons. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65(6):727–32.

16.

Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121(7):944–9.CrossRefPubMed

17.

Volpe NJ. The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results. Arch Ophthalmol. 2008;126(7):996–9.CrossRefPubMed

18.

Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology. 1999;18(2):53–63.CrossRefPubMed

19.

Warner JE, Lessell S, Rizzo III JF, Newman NJ. Does optic disc appearance distinguish ischemic optic neuropathy from optic neuritis? Arch Ophthalmol. 1997;115(11):1408–10.CrossRefPubMed

20.

Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994;118(6):766–80.CrossRefPubMed

21.•

Campbell UB, Walker AM, Gaffney M, Petronis KR, Creanga D, Quinn S, et al. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12(1):139–51. Campbell et al. were the first to demonstrate a connection between phosphodiesterase 5 inhibitor use and NAION. They found among NAION patients who use these drugs that there was a twofold increase in the likelihood of use within five half-lives of symptom onset in definitive cases. CrossRefPubMed

22.

Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. J Med Genet. 2009;46(3):145–58.PubMedCentralCrossRefPubMed

23.

Galetta SL, Cornblath WT. Should most patients with optic neuritis be tested for neuromyelitis optica antibodies and should this affect their treatment? J Neuroophthalmol. 2010;30(4):376–8. Discussion 8–9.CrossRefPubMed

24.

Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019–32.CrossRefPubMed

25.

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805–15.CrossRefPubMed

26.

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–12.CrossRefPubMed

27.

Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130(Pt 5):1235–43.CrossRefPubMed

28.

Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298(1–2):158–62.CrossRefPubMed

29.

Waters PJ, Mckeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IGG assays. Neurology. 2012;78(9):665–71. Discussion 9.PubMedCentralCrossRefPubMed

30.

Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–9.CrossRefPubMed

31.

Giovannoni G. To test or not to test: NMO-IgG and optic neuritis. Neurology. 2008;70(23):2192–3.CrossRefPubMed

32.

Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.PubMedCentralCrossRefPubMed

33.

Probstel A, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015;12:46.PubMedCentralCrossRefPubMed

34.•

Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71(3):276–83. Kitley et al. distinguished NMO patients who are NMO-IgG positive and those who are NMO-IgG negative, anti-MOG positive. They highlighted the clinical differences between these groups. CrossRefPubMed

35.

Hoftberger R, Sepulveda M, Armangue T, Blanco Y, Rostasy K, Cobo Calvo A, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015;21(7):866–74.CrossRefPubMed

36.

Nakajima H, Motomura M, Tanaka K, Fujikawa A, Nakata R, Maeda Y, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open. 2015;5(4), E007766.PubMedCentralCrossRefPubMed

37.

Kezuka T, Usui Y, Yamakawa N, Matsunaga Y, Matsuda R, Masuda M, et al. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J Neuroophthalmol. 2012;32(2):107–10.CrossRefPubMed

38.

Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197–200.CrossRefPubMed

39.

Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008;126(1):12–6.CrossRefPubMed

40.

Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324–30.CrossRefPubMed

41.

Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302–6.PubMedCentralCrossRefPubMed

42.

Pittock SJ, Lennon VA, Mckeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IGG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554–62.CrossRefPubMed

43.

Murakami Y, Yoshida S, Yoshikawa H, Yamaji Y, Ikeda Y, Ueno A, et al. CRMP-5-IGG in patient with paraneoplastic optic neuritis with lung adenocarcinoma. Eye (Lond). 2007;21(6):860–2.CrossRef

44.

Rahimy E, Sarraf D. Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management. Surv Ophthalmol. 2013;58(5):430–58.CrossRefPubMed

45.

Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49(2):146–54.CrossRefPubMed

46.

Antoine JC, Honnorat J, Camdessanche JP, Magistris M, Absi L, Mosnier JF, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001;49(2):214–21.CrossRefPubMed

47.

Sheorajpanday R, Slabbynck H, Van De Sompel W, Galdermans D, Neetens I, De Deyn PP. Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP) -5 paraneoplastic optic neuropathy. J Neuroophthalmol. 2006;26(3):168–72.CrossRefPubMed

48.

Ares-Luque A, Garcia-Tunon LA, Saiz A, Cabezas BC, Hernandez-Echebarria LE, Franco M, et al. Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies. J Neurol. 2007;254(8):1131–2.CrossRefPubMed

49.

Calvert PC. A CR(I)MP in the optic nerve: recognition and implications of paraneoplastic optic neuropathy. J Neuroophthalmol. 2006;26(3):165–7.CrossRefPubMed

50.

Sharma OP. Sarcoidosis around the world. Clin Chest Med. 2008;29(3):357–63. Vii.CrossRefPubMed

51.

Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager Jr H, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1885–9.CrossRefPubMed

52.

Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis—diagnosis and management. QJM. 1999;92(2):103–17.CrossRefPubMed

53.

Frohman LP, Guirgis M, Turbin RE, Bielory L. Sarcoidosis of the anterior visual pathway: 24 new cases. J Neuroophthalmol. 2003;23(3):190–7.CrossRefPubMed

54.

Koczman JJ, Rouleau J, Gaunt M, Kardon RH, Wall M, Lee AG. Neuro-ophthalmic sarcoidosis: the University of Iowa experience. Semin Ophthalmol. 2008;23(3):157–68.CrossRefPubMed

55.

Kawaguchi T, Hanada A, Horie S, Sugamoto Y, Sugita S, Mochizuki M. Evaluation of characteristic ocular signs and systemic investigations in ocular sarcoidosis patients. Jpn J Ophthalmol. 2007;51(2):121–6.CrossRefPubMed

56.

Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest. 1996;109(2):535–9.CrossRefPubMed

57.

Cremers J, Drent M, Driessen A, Nieman F, Wijnen P, Baughman R, et al. Liver-test abnormalities in sarcoidosis. Eur J Gastroenterol Hepatol. 2012;24(1):17–24.CrossRefPubMed

58.

Gungor S, Ozseker F, Yalcinsoy M, Akkaya E, Can G, Eroglu H, et al. Conventional markers in determination of activity of sarcoidosis. Int Immunopharmacol. 2015;25(1):174–9.CrossRefPubMed

59.

Mafee MF, Dorodi S, Pai E. Sarcoidosis of the eye and central orbit nervous system role of MR imaging. Radiol Clin N Am. 1999;37(1):73–87. X.CrossRefPubMed

60.

Vettiyil B, Gupta N, Kumar R. Positron emission tomography imaging in sarcoidosis. World J Nucl Med. 2013;12(3):82–6.PubMedCentralCrossRefPubMed

61.•

Frohman LP. Treatment of neuro-ophthalmic sarcoidosis. J Neuroophthalmol. 2015;35(1):65–72. Frohman reviewed the literature on treatment of sarcoidosis affecting the visual system. This rare and heterogeneous disorder is not amenable to systematic study. CrossRefPubMed

62.

Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. 2003;126(Pt 2):276–84.CrossRefPubMed

63.•

Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol. 2014;26(1):17–26. Petzold and Plant reviewed 122 cases of CRION published in the literature over the prior 10 years. They outlined consistent clinical features that support CRION as a distinct entity, propose diagnostic criteria, and outline treatment plans. CrossRef

64.

Doro S, Lessell S. Cup-disc ratio and ischemic optic neuropathy. Arch Ophthalmol. 1985;103(8):1143–4.CrossRefPubMed

65.

Mikkila H, Karma A, Viljanen M, Seppala I. The laboratory diagnosis of ocular Lyme borreliosis. Graefes Arch Clin Exp Ophthalmol. 1999;237(3):225–30.CrossRefPubMed

66.

Mikkila HO, Seppala IJ, Viljanen MK, Peltomaa MP, Karma A. The expanding clinical spectrum of ocular Lyme borreliosis. Ophthalmology. 2000;107(3):581–7.CrossRefPubMed

67.

Sibony P, Halperin J, Coyle PK, Patel K. Reactive Lyme serology in optic neuritis. J Neuroophthalmol. 2005;25(2):71–82.CrossRefPubMed

68.

Lanska DJ. Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. Neurology. 2008;71(2):150. Author Reply -1.CrossRefPubMed

69.

Chao JR, Khurana RN, Fawzi AA, Reddy HS, Rao NA. Syphilis: reemergence of an old adversary. Ophthalmology. 2006;113(11):2074–9.CrossRefPubMed

Titel: Atypical Optic Neuritis
verfasst von: Eric D. Gaier
Katherine Boudreault
Joseph F. Rizzo III
Julie Falardeau
Dean M. Cestari
Publikationsdatum: 01.12.2015
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 12/2015
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-015-0598-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen